Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer
Jieun Lee, Tae Ho Hong, In Seok Lee, Young Kyoung You, Myung Ah Lee
Cancer Res Treat. 2015;47(2):259-265. Published online 2014 Sep 12 DOI: https://doi.org/10.4143/crt.2013.230
Citations to this article as recorded by 
A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada
Ravi Ramjeesingh, Prosanto Chaudhury, Vincent C. Tam, David Roberge, Howard J. Lim, Jennifer J. Knox, Jamil Asselah, Sarah Doucette, Nirlep Chhiber, Rachel Goodwin
Current Oncology.2023; 30(8): 7132. CrossRef
A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer
Vivian Peirce, Michael Paskow, Lei Qin, Ruby Dadzie, Maria Rapoport, Samantha Prince, Sukhvinder Johal
Targeted Oncology.2023; 18(6): 837. CrossRef
Chemotherapy for Biliary Tract Cancer in 2021
Takashi Sasaki, Tsuyoshi Takeda, Takeshi Okamoto, Masato Ozaka, Naoki Sasahira
Journal of Clinical Medicine.2021; 10(14): 3108. CrossRef
Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis
Ting Zheng, Jianjiang Jin, Li Zhou, Yuefeng Zhang
Oncology Research and Treatment.2020; 43(9): 460. CrossRef
The Efficacy of Different Chemotherapy Regimens for Advanced Biliary Tract Cancer: A Systematic Review and Network Meta-Analysis
Yan Li, Yaoyao Zhou, Yonglan Hong, Meizhi He, Shuyi Wei, Chen Yang, Dayong Zheng, Feiye Liu
Frontiers in Oncology.2019;[Epub] CrossRef
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas
Omar Abdel-Rahman, Zeinab Elsayed, Hesham Elhalawani
Cochrane Database of Systematic Reviews.2018;[Epub] CrossRef
A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
Yi Zheng, Xiaoxuan Tu, Peng Zhao, Weiqin Jiang, Lulu Liu, Zhou Tong, Hangyu Zhang, Cong Yan, Weijia Fang, Weilin Wang
British Journal of Cancer.2018; 119(3): 291. CrossRef
Cholangiocarcinoma
Michela Squadroni, Luca Tondulli, Gemma Gatta, Stefania Mosconi, Giordano Beretta, Roberto Labianca
Critical Reviews in Oncology/Hematology.2017; 116: 11. CrossRef
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
Dae-Won Lee, Seock-Ah Im, Yu Jung Kim, Yaewon Yang, Jiyoung Rhee, Im Il Na, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, Yung-Jue Bang
Cancer Research and Treatment.2017; 49(3): 807. CrossRef
Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer
Jang Han Jung, Hee Seung Lee, Jung Hyun Jo, In Rae Cho, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Si Young Song, Jeong Youp Park
Chemotherapy.2017; 62(6): 361. CrossRef
The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis
Xin-Fang Sun, Zhi-Kuan He, Jin-Ping Sun, Quan-Xing Ge, Er-Dong Shen
Oncotarget.2017; 8(59): 100657. CrossRef